Kornimate/medical-research-clean huggingface dataset:
familial hypercholesterolemia in turkey (a-hit2)

Conditions: Familial Hypercholesterolemia; Atherosclerosis

Summary: a-hit2, is also designed as a national fh registry. at least 1000 fh patients will be recruited from 30 outpatient clinics representing the 12 nuts statistical regions in turkey proportional to the 2015 turkey's population distribution.\[14\] both hefh and hofh patients are eligible for enrollment. sites specialized on cardiology, internal medicine, and endocrinology were invited by the turkish society of cardiology.

at least 1000 fh patients will be recruited from 30 outpatient clinics representing the 12 nuts statistical regions in turkey proportional to the 2015 turkey's population distribution. both hefh and hofh patients are eligible for enrollment. sites specialized on cardiology, internal medicine, and endocrinology were invited by the turkish society of cardiology. the primary objective of this cross-sectional study, is to detect the clinical status and management of the patients diagnosed with fh in turkey. the secondary objectives are; to detect the pattern of clinical presentation, to know the medication use, to define the clinical response to llt, to evaluate the attainment of ldl-cholesterol goals and to identify resistance and/or intolerance to llt. defining the cv risk factors and approach to these factors by the physicians, and comparing the attitudes in different specialty groups (cardiology, endocrinology and internal medicine) are also among the secondary objectives of the registry. eligibility for screening was defined as having ldl-cholesterol levels \> 160 mg/dl either as on treatment or untreated values. centers may enroll both incident and prevalent patients. the inclusion criteria included age \> 18 years and being diagnosed as possible fh. the possible fh was defined as having a total score of \> 2 according to dutch lipid clinic network (dlcn) criteria. patients with triglyceride levels \> 400 mg/dl or secondary hyperlipidemia (ie, untreated hypothyroidism, nephrotic syndrome, cholestasis, etc..) will be excluded from the study. two different data sets will be collected for a-hit2. the physicians will complete electronic case report forms for each patient patients will also complete a short survey to assess the level of disease awareness. this survey is also designed to give information on the patients' perceptions and knowledge on cholesterol, its harm, and llt. all data will be collected in a single visit. data verification will be based on the source document control of 5% sample randomly selected per center.

Eligibility criteria:
inclusion criteria: * age \> 18 years and being diagnosed as possible fh. * the possible fh was defined as having a total score of \> 2 according to dutch lipid clinic network (dlcn) criteria exclusion criteria: * patients with triglyceride levels \> 400 mg/dl or secondary hyperlipidemia (ie, untreated hypothyroidism, nephrotic syndrome, cholestasis, etc..) will be excluded from the study.

Keywords: familial hypercholesterolemia registry turkey lipid lowering therapy
multi-omics characterization of pancreatic neuroendocrine tumors and carcinomas

Conditions: Cancer of Pancreas

Summary: in this work, the investigators count through the integrated multi-omics analysis to identify different tumor subgroups in pancreatic neuroendocrine tumors and carcinomas regardless of their grade and stage. to achieve this, they will resort to the use of next-generation sequencing approaches (rnaseq, then use of mcp counter for the absolute quantification of the eight populations of immune cells in the tumor microenvironment), alterations in epigenetics with study of the methylome by medip, chipseq, telomere (alt) study, as well as correlation with peripheral blood neutrophil to lymphocyte ratio and immunohistochemistry data such as ki67, p53, rb, daxx, atrx, pdl1, immune cell labeling. this will be done on frozen or paraffin material. this work will provide a more complete biological picture of pancreatic neuroendocrine tumors and carcinomas.


Eligibility criteria:
inclusion criteria: * adult patient (≥18 years old) * subject with histologically confirmed tumor or neuroendocrine carcinoma of the pancreas * subject with tumors or neuroendocrine carcinoma of the pancreas regardless of the stage of the disease * supported at the university hospitals of strasbourg between 01/01/2008 and 01/09/2019 * near therapeutic blood count available (less than 6 months) * availability of frozen and/or paraffin tumor material * patients who have already given their consent for their biological resources to be kept at the crb or in the anatomopathology department of the hus, and subsequently reused, as well as the anonymous data associated with them, for scientific research purposes. exclusion criteria: * opposition of the patient to participate in the study * diagnosis other than pancreatic neuroendocrine tumor * biological tissue from a patient who does not meet all the inclusion criteria * impossibility of giving informed information to the subject * patient under judicial protection en savoir plus sur ce texte sourcevous devez indiquer le texte source pour obtenir des informations supplémentaires envoyer des commentaires panneaux latéraux

Keywords: cancer of pancreas neuroendocrine tumors carcinoma neuroendocrine
to evaluate safety and efficacy of cgbio stent compared to biomatrix flex stent

Conditions: Ischemic Heart Disease; Stable Coronary Artery Disease; Stable Angina; Unstable Angina; NSTEMI - Non-ST Segment Elevation MI

Summary: to evaluate safety and efficacy of cgbio stent(des) compared to biomatrix flex stent(des)

a multicenter, subject-blinded, randomized study to evaluate safety and efficacy of cgbio stent compared to biomatrix flex stent in patients undergoing drug-eluting stent procedure after coronary angiography

Eligibility criteria:
inclusion criteria: * at least one lesion with a diameter stenosis \>50% * suitable for coronary stent implantation in a vessel with a reference diameter ranging from 2.5 mm to 4.0 mm; * gr 1 ≤timi flow exclusion criteria: * st-segment elevation mi * bifurcation lesion * chronic total occulusion * restenosis lesion * graft vessel lesion * patient has a history of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated or in which patient will not be able to comply with dual antiplatelet therapy for at least 1 year * cardiogenic shock or hemodynamic compromise * existing impairment in liver and kidney.
cyclic versus continuous sacral neuromodulation for luts

Conditions: Overactive Bladder Syndrome

Summary: this will be a prospective, randomized-controlled multi-site trial comparing cyclic versus continuous sacral neuromodulation (snm) for oab.

overactive bladder (oab) is characterized by urinary frequency, urgency, incontinence, and nocturia in the absence of other pathology. aua guidelines recommend trial of sacral neuromodulation (snm) for patients with refractory oab who have failed treatment with behavioral modification and medication. snm settings are typically selected based on discussion between the patient and device representative. there is a paucity of rigorous data assessing optimal snm stimulation programming for symptomatic improvement. this will be a prospective, randomized-controlled multi-site trial comparing cyclic versus continuous sacral neuromodulation (snm) in patients undergoing snm for oab. patients \> age 18 with a diagnosis of refractory oab being scheduled for a trial of snm (either stage i lead/temporary battery placement or office peripheral nerve evaluation) will be approached by study personnel during their clinic visit or by a phone call to determine if they are interested in participating in the programming study. patients interested in participating will provide written informed consent. after informed consent is obtained, a baseline evaluation will be performed. this includes history, 3-day voiding diary (# voiding episodes, # nocturia episodes, # urge incontinence episodes/24h), urinalysis, urine culture (if indicated), post void residuals, and symptom assessments using questionnaires. only those with successful trial and eligible/ interested in permanent snm placement will participate in this trial. randomization will occur after stage 2/ full permanent implantation when the neuromodulator is being programmed in the recovery room. patients will be randomly assigned to either continuous stimulation or cyclic stimulation. patients will then be followed with clinical evaluation and questionnaires repeated at 1 month, 6 months, 12 months, 3 years, and 5 years post-op.

Eligibility criteria:
inclusion criteria: * patients 18 years of age or older * female * english speaking * diagnosis of urinary urge incontinence or overactive bladder * meet criteria for and are planning permanent snm (ie. successful stage i or office pne trial of snm with 50% or more reduction in uui episodes) * willing and able to complete all study related items exclusion criteria: * patients less than 18 years of age * unable to provide consent * non-english speaking * relevant neurologic diseases (multiple sclerosis, parkinson disease, myasthenia gravis, - - - charcot-marie-tooth disease, complete spinal cord injury) * current or prior bladder malignancy
discovering ffc-mri biomarkers of alzheimer disease

Conditions: Alzheimer Disease

Summary: fast field-cycling mri (ffc mri) is a new scanning technology being developed at the university of aberdeen. previous pilot studies by the team on osteoarthritis, breast cancer, musculoskeletal cancer, liver fibrosis, thrombosis and muscle damage have demonstrated that ffc mri provides useful information for clinical diagnostics in a variety of pathologies. the aim of this study is to ascertain if brain imaging with ffc mri yields any useful information in the diagnosis and evaluation of alzheimer's disease.

alzheimer's disease (ad) patients and appropriate controls will be identified by consultants working with the patient group. potential participants will be approached by letter by their clinician. the purpose of this study will be explained to them and they will be asked for signed informed consent. communication between the clinical team and ffc-mri research team will ensure that any appointment for ffc-mri is made at a time that is convenient for the patient and clinical team. the aim is to recruit 25 individuals with ad and 25 age matched controls. ffc-mri images will be acquired on dedicated equipment specifically built for the purpose of imaging human volunteers and patients. where clinically appropriate patents will undergo other imaging procedures as part of their normal nhs care. ffc-mri will be compared standard clinical care data to identify regions of interest for quantitative analysis of ffc mri data. anonymous personal information will be collected from the nhs patient records for stratification of the results (such as age, sex or relevant examination results)

Eligibility criteria:
inclusion criteria: * patients with probable alzheimer's disease, based upon cognitive testing (mmse) and spect imaging. * controls will be participants without known cognitive impairment or alzheimer's disease. * subjects capable of giving informed consent. * age 21 and above exclusion criteria: * mri-incompatible condition detected in the mr screening sheet such as some metallic implanted devices (see mr screening sheet in the project files). * claustrophobia * waist circumference larger than 102 cm, due to the limited bore size of the scanner. * restrictions to mobility such that patients are unable to be positioned in scanner by trained research radiographer e.g. severe kyphosis * cognitive impairment of sufficient severity that the participant does not have capacity to give informed consent * pregnancy * persons who might not adequately understand verbal explanations or written information given in english, or who have special communication needs * dementia of sufficient severity that the participant cannot give informed consent
5 years follow-up with adjuvant therapy for women with breast invasive carcinoma

Conditions: Breast Cancer

Summary: non-persistence to adjuvant hormonal therapy for breast cancer at 5 years decrease its efficacy. the objective of this study is to know the women experience (persistence, treatment changes, quality of life) and its determinants, in a french population.


Eligibility criteria:
inclusion criteria: * patients following-up in the lorraine institute of oncology at 5 years of the beginning of an adjuvant hormonal therapy * women with breast invasive carcinoma positive-rh and indication of adjuvant hormonal therapy * adult patients * being capable and agree to follow the study procedure * patients informed and non-opposed * covered by social security exclusion criteria: * history of other cancer except basal cell carcinoma * patients with breast invasive carcinoma negative-rh * synchronous metastases * relapsed * previous adjuvant hormonal therapy * men * patients with guardianship

Keywords: hormone replacement therapy breast cancer follow up
role of silymarin in neuroprotection and symptom management in parkinson's disease

Conditions: Parkinson Disease

Summary: parkinson's disease (pd) is a leading neurodegenerative movement disorder, marked by a gradual loss of dopamine-producing neurons in the substantia nigra pars compacta (snpc) and the accumulation of α-synuclein protein aggregates. silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, will be studied for its neuroprotective effects in pd.


Eligibility criteria:
inclusion criteria: * age between 45 and 65 years old * both sexes * patients with parkinson's disease on dopamine replacement therapy * modified hoehn and yahr stage, mhy 1-4 (29) exclusion criteria: * subjects \< 18 years of age * pregnant or breastfeeding women * suspected hypersensitivity to silymarin or multivitamins * advanced liver disease (e.g., ascites, bleeding esophageal varices, and hepatic encephalopathy) * subjects with morbid obesity, i.e., a body mass index (bmi) \> 40 * subjects with severe illness, e.g., multisystem failure, cancer, or poorly controlled diabetes, i.e., known diabetic with hemoglobin a1c (hba1c)\>7% * current use of silymarin or recent use within the past two weeks. * other conditions, which, in the opinion of the investigators, make the patient unsuitable for enrollment.
auricular acupuncture in patients with multiple myeloma

Conditions: Multiple Myeloma; Fatigue; Pain; Depression

Summary: in the present study, the effect of ear acupressure treatment according to the nada protocol on the quality of life of patients with multiple myeloma (all stages) will be investigated. furthermore, the effect of ear acupressure on anxiety and depression, pain, fatigue and sleep of the patients will be assessed.


Eligibility criteria:
inclusion criteria: * adult patients with multiple myeloma (all stages) on current therapy, who suffer from persistent disease- or therapy-associated symptoms and limitations (screening by distress thermometer, score ≥ 5) * informed consent. exclusion criteria: * medical reasons or * a mental condition which, in the opinion of the investigator, does not allow the patient to participate in the study, * a planned radiation therapy in the area of the skull (to avoid potential scattered radiation), * a missing legally binding signature on the informed consent form, * participation in another acupuncture/acupressure study.

Keywords: auricular acupuncture
fecal microbiota transplantation and newly diagnosed ulcerative colitis (uc)

Conditions: Ulcerative Colitis

Summary: in this finuc study we are trying to find out the efficacy and safety of the fecal microbiota transplantation (fmt) in newly diagnosed active ulcerative colitis patients. the study group with newly diagnosed active ulcerative colitis receive an fmt via colonoscopy from a tested general donor, frozen and thawed from a fecal bank at week 0 and at week 4 as an enema at the study nurse´s visit. the control group will be given colored water. the main aim of the finuc study is to determine how the fmt change of the gut microbiota composition in newly diagnosed active ulcerative colitis patients. the other aim is to determine efficacy and mechanisms of fecal microbiota transplantation.


Eligibility criteria:
inclusion criteria: * over 18 years * active newly diagnosed colitis (mayo score \<11) * signed informed consent exclusion criteria: * fulminant severe colitis (mayo score 11-12 or truelove and witts criteria) * gastrointestinal infection * pregnancy * antibiotic therapy at the baseline * on-going probiotic medication * unable to provide signed informed consent
improving tissue repair after injury in the muscle-tendon interface muscle tissue injury

Conditions: Muscle Injury

Summary: the study is a 2-week human study where 40 patients who are scheduled to undergo reconstructive knee surgery are randomized to administration of gh or placebo following or without neuromuscular electrical stimulation of hamstring muscles.the overall aim is to determine, the role of muscle connective tissue protein synthesis in muscle injury and repair.


Eligibility criteria:
inclusion criteria: * healthy men and women scheduled to undergo reconstructive knee surgery * bmi 18-35 exclusion criteria: * former or current use of growth hormone or anabolic steroids * use of corticosteroids in the past 3 months * use of any medication known to affect muscle or tendon turnover * former participation in a study using deuterated water * chronic diseases
low fluoroscopy afib ablation registry

Conditions: Atrial Fibrillation

Summary: prospective data collection of patients undergoing atrial fibrillation ablation.

clinicians who have experience using low dose fluoroscopy including use of carto mapping system will consent patients to allow data collection and a 12 month f/up visit to track adverse events. clinicians will follow a protocol which will be similar to their standard of care for ablations.

Eligibility criteria:
inclusion criteria: * patient meets accepted aha/acc/hrs guideline indications for catheter ablation of paroxysmal or persistent af * first or subsequent ablation procedures may be included * age 18-75 exclusion criteria: * known venous malformations or implanted instrumentation (ivc filter) * known pv stenosis * unable to provide consent * h/o mechanical mitral valve replacement (unable to rely on ea mapping only) * documented left atrial thrombus * prior asd repair pregnancy * nyha \>=3 * ef less than 35% * chf within 90 daysrecent mi or coronary revascularization within 90 days * note: h/o implanted pacemaker or icd with transvenous leads will not be an exclusion criteria, but we will track patients treated with pre-existing transvenous leads with the hypothesis that although fluoroscopy use will be higher in these patients compared to those without leads, but still lower than conventionally treated patients. * patients who are undergoing non- standard of care ablations ie, cyro or firm ablations
influence of transcranial direct current stimulation of the primary motor cortex on pain sensation in patients suffering from fibromyalgia syndrome

Conditions: Fibromyalgia

Summary: fibromyalgia is a common chronic pain syndrome characterized by bad treatable chronic widespread pain present at a similar level for at least 3 months. the aim of this study is to examine if 3 weeks of transcranial direct current stimulation is a suitable therapy to reduce chronic pain.


Eligibility criteria:
inclusion criteria: * patients who have an established diagnosis of fibromyalgia according to the 1990 criteria of the "american college of rheumatology" * symptoms have been present at a similar level for at least 3 months * stable medication for at least 2 months * visual analog scale ≥ 3 (0=no pain; 10=worst possible pain) * the patient does not have a disorder that would otherwise explain the pain exclusion criteria: * alcohol/substance abuse * pregnancy * neuropsychiatric disorders * metal implants near stimulation area * cardiac pace maker * local injuries * inflammatory rheumatic disease * acute tumor * acute fracture * well-defined neuropathic induced pain

Keywords: widespread chronic pain, transcranial direct current stimulation, fibromyalgia
detection of efflux pump genes mediating ciprofloxacin resistance in staphylococcus aureus isolates in sohag university hospitals

Conditions: Patients withInfections Caused by S.Aureus Like Skin Infections , Chest Infections , Surgical Site Infections , and Urinary Tract Infections

Summary: among multidrug-resistant bacteria, methicillin-resistant staphylococcus aureus (mrsa) isolates were recognized to be an important mortality factor in hospital infections and a major concern in health-care and community settings . the antibiotic-resistant of s. aureus is extended by various bacterial strategies, including limiting uptake of the drug, alteration of the drugtargets, production of druginactivating enzymes and the activation of efflux pumps that effectively remove antibiotics . relying on the type of antibiotics, bacteria can apply one or more strategies. specifically, localization of resistance genes in transferable genetic elements, such as plasmid and transposons , causing horizontal transfer of resistance genes between bacterial strains . mrsa strains are resistant to nearly all beta-lactam antibiotics by producing an alternative penicillin-binding protein known as pbp2a . this protein is encoded by the meca gene and has a low affinity to manybeta-lactam antibiotics. furthermore, these strains often show resistance to a wide range of antibiotics . the use of fluoroquinolone for the effective infectious therapy is limited by presence of fluoroquinolone resistance . there are two mechanisms causing resistance to fluoroquinolone. the first one is attributed to mutations occurring in the quinolone-resistance determining region (qrdr) of topoisomerase iv encoded by grla/grlb and dna gyrase encoded by gyra/gyrb; these mutations decrease the affinity ofthe drug. the other mechanism is mediated by efflux pumps which is less recognized . recently, several efflux pumps have been identified for s. aureus including efflux pumps encoded by chromosome or plasmids. the efflux pumps nora, norb, norc, mdea, sepa, mepa, sdrm and lmrs are encoded by chromosome while qaca/b, qacg, qach, qacj and smr are plasmid-encoded . efflux pumps could be specialized for specific substrate or mobilized a wide varieties of different antibiotic classes . despite, efflux pumps can potentially increase resistance to antibiotics in clinical isolates of s. aureus, few studies have been evaluated the individual and collective participation of the efflux system in resistant isolates . therefore the aim of the study is to detect ciprofloxacin resistant strains of staphylococcus aureus isolates and to detect efflux pump genes ( nora , norb and norc ) mediating resistance in such strains.


Eligibility criteria:
inclusion criteria: * infections caused by s.aureus like skin infections , chest infections , surgical site infections , and urinary tract infections exclusion criteria: * infections caused by any organisms other than s.aureus